For a year Medicube's brightening line was built on kojic acid and turmeric, ingredients that gave the products their name and their colour while sitting far down the list at doses nobody would call therapeutic. Then in April 2025 the brand released this serum and printed three numbers on the box: 5 percent tranexamic acid, 10 percent niacinamide, 2 percent arbutin. That is a different kind of product, and a different kind of confidence. It is the ingredient-forward disclosure that the Western serum brands made standard, adopted by a K-beauty company that had been selling stories, and the reason it matters is that the numbers are the right ones.
Take them in turn. Tranexamic acid at 5 percent sits at the top of the range the topical trials have used, and its mechanism is the thing that makes the serum more than another tyrosinase inhibitor: it damps the plasmin signalling by which UV and inflammation tell melanocytes to overproduce, working upstream of pigment synthesis, which is why it has become a mainstay of melasma treatment and why a 2024 split-face randomized trial in skin of colour found a 3 percent cream comparable to 4 percent hydroquinone for mixed-type melasma over twelve weeks. Niacinamide at 10 percent, second in the list, blocks the transfer of finished melanosomes into skin cells and rebuilds barrier lipids, a dose supported by trials at 2 to 5 percent and pushed here to the ceiling most formulators consider before flushing becomes common. Arbutin at 2 percent, the glycoside that releases a little hydroquinone in skin, inhibits tyrosinase directly. Signalling, synthesis, transfer: three pathways, three disclosed doses, in one thin serum.
The base is what keeps a 15 percent active load usable. Ten forms of hyaluronic acid fill the back third of the list with panthenol and betaine above them, so the serum feels light and hydrating rather than tight, and that is what Medicube's 72-hour contract-lab panel actually measured: a hydration gain and a small clarity gain in three days. It is honest of the brand to have measured hydration, since no brightener does anything measurable to pigment in seventy-two hours, and it is also a reminder that the serum's real evidence is the trial literature on its actives, not a test of the bottle. A trio of ferulic acid, glutathione and vitamin B12 in the twenties adds antioxidant vocabulary and the pink tint, which pales in light and, as the brand's own FAQ says, changes nothing. Three peptides close the list at trace.
In use it is undramatic in the best way. A few drops sink in within a minute, sit under sunscreen or a retinoid without pilling, and leave skin a touch dewy; by the third day skin looks slightly clearer, and the marks it is bought for begin to soften around the one-month point, with the three-thousand-odd Amazon reviewers who rate it four and a half stars most consistent about post-acne marks fading over two months. Melasma is slower and needs the full twelve weeks with strict sunscreen to judge, and it will return when the sunscreen lapses, which is true of every melasma product ever sold.
The cautions are specific. Ten percent niacinamide produces a warm tingle or a flush in a meaningful minority, especially over freshly exfoliated skin, and it usually settles within a week; reactive faces should start once daily on dry skin and drop to a lower-niacinamide brightener if it persists. The serum is marketed as fragrance-free, which is true in the narrow sense that nothing is labelled parfum and false in the sense that matters, because Rosa centifolia flower oil sits at twenty-second, a rose essential oil that is the formula's one real sensitiser and an odd inclusion in a product aimed at inflamed, post-acne skin. And two cosmetic quirks confuse people: the pink fades, and a white crust of niacinamide can crystallise at the dropper, neither of which means anything.
Medicube, APR Corporation's skincare brand since 2014, is better known for pads and jelly masks and for panels that measure what is easy to measure, and it is fair to say that the brand's evidence for this serum is thin while the evidence for its ingredients is strong. At twenty-four dollars for 30 millilitres, roughly two months of twice-daily use, it undercuts most Western tranexamic acid serums by a wide margin while matching or exceeding their doses, and that arithmetic is the reason to buy it.
So credit the numbers on the box. This is the serum Medicube's brightening line should have led with: three actives at doses the trials support, disclosed, in a hydrating base, at a drugstore-adjacent price, with a rose oil it should not have added and a niacinamide dose that reactive skin will feel. For post-acne marks, sun spots and melasma maintenance it is a serious option, provided the sunscreen is as serious.
